Last reviewed · How we verify
EPIAO®
EPIAO® is a marketed drug by Shenyang Sunshine Pharmaceutical Co., LTD., with an unknown mechanism of action and unspecified primary indication. The key composition patent for EPIAO® is set to expire in 2028, which may provide a period of market exclusivity. The primary risk is the lack of detailed clinical trial results and revenue data, which could impact investor confidence and market positioning.
At a glance
| Generic name | EPIAO® |
|---|---|
| Also known as | Recombinant human erythropoietin |
| Sponsor | Shenyang Sunshine Pharmaceutical Co., LTD. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study) (PHASE3)
- Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study) (PHASE4)
- PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EPIAO® CI brief — competitive landscape report
- EPIAO® updates RSS · CI watch RSS
- Shenyang Sunshine Pharmaceutical Co., LTD. portfolio CI